$ACT Company News Actavis expects profit to beat

New Post Public Reply Private Reply Replies (0) Message Board

Jan 13, 2015 at 12:09 PM

$ACT Company News

Actavis expects profit to beat expectations 9:44 a.m. Jan. 12, 2015 - Michael Calia
Drug trials, upgrades boost health-care sector 11:57 a.m. Jan. 8, 2015 - Russ Britt
10 stocks that can withstand a rocky 2015 12:31 p.m. Dec. 31, 2014 - The Trading Deck
Eight charts plot the year in finance 12:45 p.m. Dec. 30, 2014 - Ophir Gottlieb
Here are the best S&P 500 stocks and sectors of 2014 1:52 p.m. Dec. 29, 2014 - Philip van Doorn
2014 was the year that all predictions were wrong 11:29 a.m. Dec. 26, 2014 - Marek Fuchs
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Adamas' stock soars after dementia treatment approval 8:24 a.m. Dec. 24, 2014 - Tomi Kilgore
Second 2% S&P 500 spike signals strong bull trend 11:23 a.m. Dec. 19, 2014 - Michael Ashbaugh
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane

Celgene, Bristol-Myers Cancer Drug News Lifts Stocks 5:48 p.m. Jan. 12, 2015 - Investors Business Daily
Celgene Says Q4 Earnings Beat, Sees Currency Impact 12:52 p.m. Jan. 12, 2015 - Investors Business Daily
3 Stocks Advancing The Drugs Industry 12:13 p.m. Jan. 12, 2015 - TheStreet.com
Digging Deeper: Outperforming Stocks In The Leading Health Care Sector 12:10 p.m. Jan. 12, 2015 - Seeking Alpha
FTC grants early termination of HSR waiting period for Actavis/Allergan deal 9:34 a.m. Jan. 12, 2015 - Seeking Alpha
Actavis Profit to Beat Expectations 9:21 a.m. Jan. 12, 2015 - The Wall Street Journal Interactive Edition
Actavis (ACT) Off To A Strong Start In Pre-Market Activity 9:10 a.m. Jan. 12, 2015 - TheStreet.com
Four Best Gains In IBD 50: Nothing To Do With Oil 5:35 p.m. Jan. 9, 2015 - Investors Business Daily
Jim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panic 8:23 p.m. Jan. 8, 2015 - TheStreet.com
Four Hot Growth Stocks To Put On Your Watch List 5:06 p.m. Jan. 8, 2015 - Investors Business Daily
Adamas earns milestone from Actavis 4:19 p.m. Jan. 8, 2015 - Seeking Alpha
Actavis' Appeal Case for Namenda Gets Accelerated Hearing - Analyst Blog 4:35 p.m. Jan. 7, 2015 - Zacks.com
KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog 2:28 p.m. Jan. 7, 2015 - Zacks.com
10 Stocks Every Millennial Should Add to Their Portfolio Right Now 11:37 a.m. Jan. 7, 2015 - TheStreet.com
Health-Care Stocks Avoid Malaise 8:34 p.m. Jan. 6, 2015 - The Wall Street Journal Interactive Edition
Will Allergan Buy Help Actavis Extend Growth Streak? 5:17 p.m. Jan. 6, 2015 - Investors Business Daily
Merger Arbitrage Mondays - January 5, 2015 6:34 a.m. Jan. 5, 2015 - Seeking Alpha
IBD 50 Tone Darkens; More Leaders Below 10-Week Line 5:13 p.m. Jan. 2, 2015 - Investors Business Daily
An Investor's Guide: Market-Leading Industries In 2014 1:57 p.m. Jan. 2, 2015 - Investors Business Daily
Activists Are on a Roll, With More to Come 5:08 p.m. Jan. 1, 2015 - The Wall Street Journal Interactive Edition

Actavis Launches U.S. Generic Specialty Injectable Portfolio 8:00 a.m. Today - PR Newswire - PRF
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom 8:35 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance 8:30 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:02 a.m. Jan. 12, 2015 - BusinessWire - BZX
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR 3:54 p.m. Jan. 6, 2015 - PR Newswire - PRF
Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine 2:00 a.m. Jan. 6, 2015 - PR Newswire - PRF
Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis 9:00 a.m. Dec. 29, 2014 - PR Newswire - PRF
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 1:15 p.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 8:00 a.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer 9:24 a.m. Dec. 22, 2014 - PR Newswire - PRF
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults 4:15 p.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 9:00 a.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition 7:30 a.m. Dec. 16, 2014 - PR Newswire - PRF
Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR 3:11 p.m. Dec. 15, 2014 - PR Newswire - PRF
Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 4:46 p.m. Dec. 5, 2014 - PR Newswire - PRF
No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan, an Industrial Info News Alert 6:15 a.m. Dec. 3, 2014 - Marketwired
Stock Updates on Pharma Services - Avanir Pharma, Zoetis, Allergan, Mallinckrodt, and Actavis 8:30 a.m. Nov. 25, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Memoir 'Pinball' Explores Life's Unpredictable Momentum

Funny how some folks think life has a road map. Let me tell you, it's more like a pinball machine, barely controllable and ready to surprise you with a tilt at any moment. And that's the essence of Marshall Barber's new memoir, 'PINBALL: Remembrances of a Flaneur.' Life's Roulette: Choices and Chance Barber takes readers on a raw ride through the byways of a life...

YR Fitness Rolls Out Innovator's Iron at FIBO 2027

A New Era of Strength Training Equipment? That's the question I asked myself when I heard about YR Fitness showcasing their latest gym gear at FIBO 2027. This isn't just another batch of machines rolling off the production line. YR Fitness has become quite the icon in China for strength equipment, and they're dead set on shaking up the market in Cologne, Germany from...

PG&E, Edison Push Liability Cap Amid Firestorm

The Thanksgiving Playbook Nobody Wanted Sacramento's corridors are buzzing with electric tension. And why? It's not some trivial turkey drama but a simmering scandal over two utility giants trying to sneak a liability cap into law faster than you can ask for a second slice of pumpkin pie. PG&E and Edison have a little secret—a covert strategy to limit shareholder...

Oracle's $20 Billion Offering: What Investors Need to Know

Oracle's Big Play: A $20 Billion Offering Nobody said playing in the big leagues was easy, and Oracle seems to be doubling down on that idea. Today, they spilled the beans on their ambition to rake in a cool $20 billion through an offering of common stock and senior notes. For those of us who keep a close eye on NYSE:ORCL, this is more than just a number—it's a signal...

Alfa Laval's Market Outlook: Strategic Plans Ahead

Alfa Laval's Vision for the Future Alfa Laval is gearing up for a dynamic Capital Markets Day on November 18, 2026. The Swedish engineering giant, renowned for heat transfer, separation, and fluid handling solutions, is setting the stage to outline bold strategies and ambitious targets. Investors should pay attention, as the company's roadmap charts a course towards a SEK...

ALS Research Gains Momentum as ACT for ALS Law Signed

A Major Stride in ALS Advocacy Today's not your usual day at the office for the folks championing the fight against ALS. With the President putting pen to paper, the ACT for ALS Act just turned into law, sending ripples through the community. Let me tell ya, legislation like this doesn't float by on a cloud—it's the result of grit, sleepless nights, and a dash of...

WareSpace Expands in U.S. with Key Site Acquisitions

WareSpace's National Growth Strategy: A New Expansion Chapter They say everything's bigger in Texas, but WareSpace is showing that smaller can be mighty impactful too. With its shrewd acquisition of sites in Houston's Inner Loop and Fremont's Warm Springs corridor, WareSpace is playing it smart, appeasing that roaring demand for tiny but mighty warehouse spaces across...

LITE, RRC, SGRY: Are Shareholders Getting Shortchanged?

What's Really Going On Here? Here's the skinny: Halper Sadeh LLC, that hard-hitting investor rights law firm, is poking their noses into some potential red flags over at a few companies you might have heard of—Lumentum Holdings (NASDAQ:LITE), Range Resources (NYSE:RRC), and Surgery Partners (NASDAQ:SGRY). They're sniffing around transactions that might leave the regular...

Kia's Thunderous October Sales Surge: What's Under the Hood?

Electric Pulse: Kia's Electrified Dreams Soar No one said the road to the top is easy, yet Kia America is cruising along with six straight months of shattering sales records. October's monumental figures paint the picture clear as a bell — 80,008 units dispatched to eager drivers, with electrified and hybrid models zooming to new heights. It ain't just the same old...

TEKLYNX 2026: Revolutionizing Barcode Labeling Tech

In the ever-evolving world of supply chain technology, a big move by TEKLYNX is making waves. The 2026 version of their barcode labeling software isn't just an upgrade—it's a full-blown transformation. They've fine-tuned their suite to align with the latest industry standards and integrated fresh capabilities that scream future-proofing. TEKLYNX's Game-Changing Upgrades...